Overview of human papillomavirus vaccination policy changes and its impact in the United States: Lessons learned and challenges for the future

Public Health Nurs. 2021 May;38(3):396-405. doi: 10.1111/phn.12873. Epub 2021 Feb 10.

Abstract

Background: The HPV vaccination is effective and safe for preventing HPV infection and HPV attributable cancers. Despite this fact, the uptake rate of the vaccination in the United States has remained below the national target of 80%. Health policy focused on allocating resources and creating vaccine-promoting environments can influence HPV vaccination coverage rates. There is a scarcity of information about the HPV vaccination-related health policy and its impact on the outcome of vaccine uptake.

Method: We conducted a comprehensive review of HPV vaccination-related health policies at the federal, state, and professional organization levels and examined their impact on population health by reviewing national data on HPV vaccination uptake rates.

Results: The review revealed that (a) HPV vaccination recommendations, which serve as the federal-level HPV vaccination policy, have changed frequently in terms of gender, age criteria, and dosing schedule, and (b) the frequent changes of the policy have resulted in low uptake rates among male and young adult populations.

Discussion: The uptake rate should be continuously followed to evaluate the impact of recent changes to the federal-level HPV vaccination policy. State-level policies and healthcare professionals, including nurses, are important to the promotion of HPV vaccinations and decreasing HPV vaccination disparities.

Keywords: Papillomavirus vaccine; health policy; immunization; policy implementation; population health.

Publication types

  • Review

MeSH terms

  • Alphapapillomavirus*
  • Health Policy
  • Humans
  • Male
  • Papillomavirus Infections* / epidemiology
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines*
  • United States
  • Vaccination
  • Young Adult

Substances

  • Papillomavirus Vaccines